Promise Launches Doctor-Guided Compounded Sermorelin Program Amid FDA Peptide Scrutiny

Scottsdale, Arizona, USA, October 20th, 2026, FinanceWire

The Scottsdale telehealth company is publishing an analysis examining the distinction between doctor-guided compounded sermorelin and peptides marketed online as “research use only,” following recent FDA warning letters.

Promise today announced the release of a new analysis examining how prescription-based clinical review, pharmacy compounding, and online peptide marketing differ. Promise provides additional context on how patients can distinguish between doctor-guided treatment pathways and peptide products marketed online for research purposes. Promise focuses on sermorelin and the distinction between a provider-reviewed prescription pathway and products marketed with research-use or not-for-human-consumption disclaimers.

Promise's program uses a treatment-specific online clinical questionnaire reviewed by a licensed provider in its prescribing network. The provider determines whether a prescription is appropriate, and prescriptions are filled by licensed U.S. compounding pharmacies. Not every patient qualifies for treatment. Patients seeking Sermorelin through Promise follow this provider-reviewed process rather than purchasing the medication as a general retail product. 

FDA Warning Letters Put Research-Use Disclaimers Under Scrutiny

The FDA issued five warning letters dated August 24, 2026, to online peptide sellers, classifying the products described in those letters as unapproved new drugs and misbranded products. The FDA said that statements such as “research use only” and “not for human consumption” did not control where other evidence on the sellers' websites indicated intended human use.

The findings apply to the specific sellers and evidence identified by the FDA. They do not establish that every product carrying a research-use disclaimer is unlawful or that every research-use seller has been subject to the same findings. For Promise, the warning letters underscore the distinction between online peptide marketing and a prescription process that involves review by a licensed provider.

Compounded Sermorelin and FDA Approval are Different Questions

The FDA states that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness, or quality before marketing. Compounding can nevertheless serve specific medical needs under federal requirements governing pharmacy compounding.

Promise's compounded sermorelin is not FDA-approved. Historical FDA records show that sermorelin acetate, marketed as Geref, received marketing approval in 1997. That historical approval concerns the Geref product and should not be interpreted as FDA approval of a current compounded sermorelin formulation. Promise does not represent its compounded sermorelin as an FDA-approved product, and its prescribing process remains subject to provider review and applicable requirements.

Sermorelin has also become part of the broader commercial discussion around peptide-based telehealth. Reuters reported in August 2026 that a major consumer telehealth company planned to offer legally available peptides, including sermorelin, by the end of the year. The report described a wider market in which some peptides are available while others remain subject to regulatory review.

Methodology

Promise's analysis is based on FDA warning letters issued in August 2026, current FDA information on compounded drugs, historical FDA records concerning sermorelin acetate, Reuters reporting published August 12, 2026, and company-provided information about Promise's prescribing process. No proprietary patient survey, safety study, or efficacy study was conducted.

Frequently Asked Questions:

How is Sermorelin Prescribed Through Promise?

Promise uses an online clinical questionnaire for each treatment. A licensed provider reviews the information and determines whether a prescription is appropriate. If prescribed, the medication is filled by a licensed U.S. compounding pharmacy.

Is Compounded Sermorelin FDA-Approved?

Promise's compounded sermorelin is not FDA-approved. The FDA states that compounded drugs do not undergo the agency's premarket review for safety, effectiveness, or quality. Historical FDA records separately document the approval of Geref, a sermorelin acetate product, in 1997.

What Did the August 2026 FDA Warning Letters Change?

Promise notes that the warning letters highlighted that “research use only” or similar disclaimers do not necessarily determine how the FDA views a product when other website evidence indicates intended human use. The letters were directed at five specific online peptide sellers.

About Promise

Promise is a telehealth company based in Scottsdale, Arizona, founded in 2026. The company provides doctor-guided telehealth programs for peptide therapy, weight management, and hormone care through online clinical questionnaires and a network of licensed providers.

Contact